Telavancin: a novel lipoglycopeptide

Clin Infect Dis. 2009 Dec 15;49(12):1908-14. doi: 10.1086/648438.


Telavancin, a derivative of vancomycin, is a lipoglycopeptide antibiotic that has been shown to be effective for the treatment of complicated skin and skin-structure infections. It has also been effective in the treatment of gram-positive pneumonia. This antibiotic has a dual mechanism of action by inhibiting peptidoglycan synthesis and causing membrane depolarization. Telavancin is consistently active against Staphylococcus aureus, including methicillin-resistant S. aureus, vancomycin-intermediate S. aureus, linezolid-resistant S. aureus, and daptomycin-nonsusceptible strains. The drug is usually administrated intravenously at 10 mg/kg every 24 h. Telavancin is excreted by the kidneys, and thus, dosage adjustments are required in cases of renal failure. Clinical trials have demonstrated non-inferiority, compared with vancomycin, in the treatment of complicated skin and skin-structure infections and pneumonia. Telavancin is associated with higher rates of renal events, altered taste, nausea, and vomiting but lesser rates of pruritus and infusion-related events, compared with vancomycin.

Publication types

  • Review

MeSH terms

  • Aminoglycosides / adverse effects
  • Aminoglycosides / pharmacokinetics
  • Aminoglycosides / pharmacology*
  • Aminoglycosides / therapeutic use
  • Anti-Bacterial Agents / pharmacology*
  • Chemistry, Pharmaceutical
  • Humans
  • Lipoglycopeptides


  • Aminoglycosides
  • Anti-Bacterial Agents
  • Lipoglycopeptides
  • telavancin